Rewalk Robotics Ltd
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Rewalk Robotics' stock with a target price of $13, indicating strong potential for growth.
Financial Health
Rewalk Robotics is generating decent revenue and cash flow, but its profitability is somewhat limited.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LFWD
Immersive Rehab & VR Therapy
Virtual and augmented reality are transforming healthcare with innovative digital treatments for physical and psychological healing. These carefully selected companies are at the forefront of creating immersive technologies that offer effective alternatives to traditional therapies, poised to benefit from growing clinical acceptance.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Medical innovation focus
Works on wearable exoskeletons that could change mobility care; regulatory and clinical acceptance are crucial, and outcomes can affect prospects.
Micro‑cap dynamics
With a market cap near $10.7M the stock can be volatile and less liquid — potential for upside but higher risk and price swings are possible.
Market access matters
Growth depends on approvals, reimbursement and partnerships across regions; commercial execution is as important as the technology itself.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
